The next era of liposomal delivery: Lessons from s-equol

Liposomes have been part of pharmaceutical science for more than half a century.

First described in the 1960s, lipid-based vesicles have evolved from a laboratory discovery into an established drug-delivery technology, with applications ranging from oncology to nucleic acid and vaccine delivery.^1-2

Their growing presence in dietary supplements reflects a broader shift in the industry: formulation is increasingly weighed alongside ingredient selection when products are built around bioavailability.

But the rapid adoption of the term “liposomal” has also raised a new question for supplement developers: what actually makes a liposomal formulation work?

A phospholipid-containing formulation is not necessarily a functional liposome. Particle morphology, size distribution, encapsulation efficiency, release behavior, stability under gastrointestinal conditions, and, ultimately, pharmacokinetic performance all matter when assessing whether a delivery system provides a meaningful advantage.

This is especially relevant for bioactive compounds whose biological potential is well established but whose oral performance is limited by physicochemical and metabolic barriers. S-equol is one such example.

S-Equol: A well-studied compound with a formulation challenge

S-equol is a metabolite produced when certain intestinal bacteria convert the soy isoflavone daidzein. Its molecular structure resembles 17β-estradiol, and s-equol has a relatively selective affinity for estrogen receptor beta (ERβ).^3-4

Research has investigated s-equol in areas including menopausal health, bone health, cardiovascular health, and skin health.⁴

Yet the ability to produce s-equol from soy isoflavones is not universal. Only a proportion of the population carries the intestinal microbiota capable of converting daidzein into s-equol, and reported conversion rates vary across populations.⁵

This has created a straightforward rationale for direct s-equol supplementation: rather than relying on an individual’s ability to produce s-equol from soy isoflavones, the active metabolite can be supplied directly.

The challenge then moves from conversion to delivery

S-equol is a lipophilic small molecule with very low aqueous solubility, and its oral disposition is further shaped by intestinal transport, metabolism, and conjugation.

In a Caco-2 cell model, s-equol underwent intestinal transport, while much of the compound recovered after four hours were present as glucuronide and sulfate conjugates – a reminder of how much absorption and metabolism determine its actual availability.⁶

For formulation developers, these properties translate into several practical challenges:

• Low aqueous solubility can limit dissolution in gastrointestinal fluids
• Intestinal and first-pass metabolism can further reduce systemic exposure after oral intake
• Relatively rapid disposition may limit how long measurable levels of the compound are maintained in the body

Put simply, s-equol’s biological credentials are not in question. What is in question is how efficiently a given oral formulation delivers it to the body.

Why liposomes are relevant to s-equol

Liposomes are vesicular structures formed by phospholipid bilayers. Their amphiphilic architecture lets them incorporate lipophilic compounds within the lipid membrane while maintaining an aqueous compartment inside the vesicle.

For poorly water-soluble compounds, this architecture can offer several formulation advantages.

Improving dispersion of a poorly water-soluble compound

In a conventional formulation, a highly lipophilic compound has limited interaction with the aqueous environment of the gastrointestinal tract. Encapsulating it within a lipid-based vesicle can improve dispersion and create a more favorable formulation environment for an otherwise poorly water-soluble ingredient.

Particle size is an important formulation parameter here: smaller, more uniformly distributed particles can influence dispersion, physical stability, and interactions with biological interfaces. Research into lipid-based oral delivery systems has also examined intestinal lymphatic transport as one potential pathway for improving systemic exposure to lipophilic compounds.⁷

Modulating release

A liposomal system can also influence how an encapsulated compound is released. Rather than delivering the entire dose as freely dispersed material, the phospholipid bilayer can act as a formulation matrix that shapes the release and disposition of the active ingredient.⁸

Extending exposure time is not the goal in itself. What matters for supplement developers is whether the formulation change produces a measurable improvement in exposure or other meaningful pharmacokinetic outcomes.

Providing a protective formulation environment

Lipid-based carriers can also provide a physical environment that helps protect sensitive compounds from unfavorable conditions during gastrointestinal transit.

That said, the biological fate of lipid-based nanoparticles is complex and depends on particle characteristics, lipid composition, digestion, and interactions with the gastrointestinal environment.⁹ This is why a liposome needs to be evaluated as a complete delivery system, not simply as an ingredient combined with a phospholipid.

From “liposomal” as a label to performance as a standard

As liposomal delivery becomes more common in the nutrition and supplement industry, the criteria used to evaluate these products are evolving as well.

Historically, encapsulation efficiency was often treated as the headline specification. But encapsulation alone does not establish whether a formulation actually improves oral performance. A more complete assessment should consider several parameters together:

• Particle size and size distribution
• Polydispersity Index (PDI) and physical uniformity
• Morphology
• Encapsulation efficiency
• Active-content stability
• Release behavior
• Stability under simulated gastrointestinal conditions
• Pharmacokinetic performance
• Where appropriate, comparative human absorption data

For Bonerge’s BonVesio^TMs-equol liposomal formulation, these parameters offer a more meaningful framework for understanding what the delivery technology actually contributes.

Performance depends on the specific formulation, manufacturing process and test conditions. These characteristics should not be assumed solely from the use of a “liposomal” label. The value of a delivery technology ultimately lies in what can be demonstrated, not in the terminology used to describe it.

Building a more data-driven liposomal platform

For Bonerge Lifescience, this means building a liposomal delivery platform around measurable formulation parameters rather than treating liposomes simply as a marketing format. Three areas matter most.

Standardized manufacturing

A functional liposomal system requires control over the parameters that define its physical and chemical characteristics – including particle size distribution, PDI, encapsulation efficiency, and active-content stability over time.

The BonVesio^TMs-equol, for example, is designed around a controlled nanoscale particle range, with a target particle size of approximately 100nm to 200 nm, PDI below 0.2 and encapsulation efficiency above 85%.

These specifications are not an endpoint in themselves; they provide the foundation for batch-to-batch consistency and the biological evaluation that follows.

Transparent characterization

A delivery system should be supported by data generated at multiple stages. For liposomal formulations, this can include in vitro release profiles, stability under simulated gastrointestinal conditions, particle characterization and, where appropriate, animal pharmacokinetic studies and human comparative absorption studies, building a more complete evidence chain from what the formulation looks like to how it behaves in a biological environment.

A platform rather than a single product

S-equol is a useful case study because its formulation challenge is closely tied to its physicochemical properties, but the underlying delivery technology has broader potential.

The same platform approach can be applied to other actives characterized by poor aqueous solubility, limited oral exposure, or substantial metabolic challenges, with the goal of a repeatable formulation strategy adaptable to different ingredients and finished-product formats.

What comes next for liposomal nutrition?

The supplement industry’s interest in liposomes is unlikely to be driven by the word “liposomal” alone for much longer. As brands become more sophisticated and consumers become more familiar with delivery technologies, the relevant questions are changing:

• How small are the particles?
• How stable is the system?
• How efficiently is the active encapsulated?
• How does it behave during digestion?
• Most importantly: does the formulation change what the body is actually exposed to?

S-equol illustrates why these questions matter. The ingredient has a well-established biological rationale, but its formulation characteristics present a separate development challenge. Liposomal delivery offers one technological route to address that challenge – though the value of the approach still needs to be demonstrated through formulation characterization and biological data.

Putting an ingredient inside a liposome is the easy part. What will set the next generation of liposomal nutrition apart is proof of what that liposome actually changes for the body.

For ingredient developers, that shift from formulation concept to measurable performance is a meaningful step in the maturation of lipid-based delivery for dietary supplements.

Find out more about EquoYouth S-equol.

References

1. Bangham, AD.; et al. Negative staining of phospholipids and their structural modification by surface-active agents as observed in the electron microscope. J Mol Biol. 1964;8:660–668.
2. Allen, TM.; et al. Liposomal drug delivery systems: From concept to clinical applications. Adv Drug Deliv Rev. 2013;65(1):36–48.
3. Setchell, KDR,; et al. Equol: History, chemistry, and formation. J Nutr. 2010;140(7):1355S–1362S.
4. Jackson, RL.; et al. Emerging evidence of the health benefits of S-equol, an estrogen receptor β agonist. Nutr Rev. 2011;69(8):432–448.
5. Setchell, KDR.; et al. Method of defining equol-producer status and its frequency among vegetarians. J Nutr. 2006;136(8):2188–2193.
6. Walsh, KR.; et al. Transport and metabolism of equol by Caco-2 human intestinal cells. J Agric Food Chem. 2009;57(18):8297–8302.
7. Daeihamed, M.; et al. Potential of liposomes for enhancement of oral drug absorption. Curr Drug Deliv. 2017;14(2):289–303
8. Porter, CJH.; et al. Lipids and lipid-based formulations: Optimizing the oral delivery of lipophilic drugs. Nat Rev Drug Discov. 2007;6(3):231–248.
9. Wang, T.; et al. Biological fate of ingested lipid-based nanoparticles: Current understanding and future directions. Nanoscale. 2019;11(23):11048–11063